Status:

COMPLETED

Investigating the Use of Complex Pulse Shapes for DBS in Movement Disorders

Lead Sponsor:

KU Leuven

Conditions:

Parkinson Disease

Essential Tremor

Eligibility:

All Genders

18-99 years

Phase:

NA

Brief Summary

Parkinson's disease and essential tremor are chronic movement disorders for which there is no cure. When medication is no longer effective, deep brain stimulation (DBS) is recommended. Standard DBS is...

Detailed Description

The study had three stages. In the first stage, a wide range of investigatory pulse shapes in a small number of patients. The effect of the pulses on the therapeutic window will be assessed. Stage 2 ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for PD:
  • Diagnosis of idiopathic Parkinson's disease where the diagnosis was made by a Movement Disorder Specialist according to the MDS criteria of 2015, with a Hoehn and Yahr scale (H\&Y) of at least 2 (bilateral involvement).
  • Onset of the symptoms more than five years ago.
  • MDS-UPDRS-III score of ≥30 without medication or DBS.
  • Electrodes are implanted in target area STN.
  • Inclusion Criteria for ET:
  • Patient is diagnosed with essential tremor by a Movement Disorder Specialist.
  • Diagnosis since more than 3 years.
  • Patient has a disabling medical-refractory upper extremity tremor without medication or DBS.
  • Patient has a postural or kinetic tremor severity score of at least 3 out of 4 in the extremity intended for treatment on the Fahn-Tolosa-Marin Clinical Rating Scale for Tremor without medication or DBS.
  • Electrodes are implanted in target area VIM.
  • General
  • Post-op the implanted electrodes pass an integrity check, i.e. no open or shorted electrodes.
  • Stable medications
  • Lack of dementia or depression.
  • Patient is willing and able to comply with all visits and study related procedures
  • Patient understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed.
  • Patient can tolerate at least 12 hours OFF medication and per clinical judgement be able to perform all study related procedures

Exclusion

  • Any significant psychiatric problems, including unrelated clinically significant depression.
  • Any current drug or alcohol abuse.
  • Any history of recurrent or unprovoked seizures.
  • Have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival \<12 months.

Key Trial Info

Start Date :

February 12 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 14 2022

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT04725045

Start Date

February 12 2019

End Date

April 14 2022

Last Update

April 29 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

KU Leuven

Leuven, Belgium, 3000